Nifurtimox Production Cost Reports

The report provides a detailed analysis essential for establishing a nifurtimox production plant. It encompasses all critical aspects necessary for nifurtimox production, including the cost of nifurtimox production, nifurtimox plant cost, nifurtimox production costs, and the overall nifurtimox production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a nifurtimox production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Nifurtimox is a medicinal compound that is mainly used in the healthcare and medical industry. It is primarily utilised as an important drug for the treatment of Chagas disease, which is a parasitic infection caused by Trypanosoma cruzi. It is used to treat Chagas disease in adults and in children who are less than 18 years of age and weigh at least 2.5 kg. It is also used in combination with other drugs like eflornithine for the management of African sleeping sickness in certain cases. It works by producing harmful substances inside the parasite, which damage it and stop its growth. Moreover, it has also been explored for its role in combination therapies for specific paediatric cancers, such as neuroblastoma. It is widely produced and supplied for hospitals, clinics, and public health programs in regions where parasitic diseases are common. It is also used as a reference drug in scientific research to study antiparasitic drug development and infectious disease treatment methods.

The market for nifurtimox is primarily driven by its application as an antiprotozoal agent in treating serious parasitic illnesses, which boosts its demand in the medical sector. Its application as an antiprotozoal prescription medicine for the treatment of Chagas disease in paediatric patients (less than 18 years of age) significantly promotes its demand in the pharmaceutical industry. Its usage as an oral medication in combination with other antiparasitic agents for African sleeping sickness further adds to its demand in the pharmaceutical and healthcare industries.

Its application as a potential antineoplastic agent in cancer therapy, especially in treating certain types of tumours in children, also fuels its demand in the medical and oncology sectors. Its demand as an important drug in hospitals, clinics, and public health programs for tropical disease control further supports its market growth. Several factors, including the cost and availability of raw materials, regulatory approvals, and strict quality and safety standards, significantly influence industrial nifurtimox procurement. Moreover, improvements in pharmaceutical production processes, supplier reliability, compliance with global health regulations, sustainability practices, and efficient supply chain management largely impact procurement processes globally.

Raw Material for Nifurtimox Production

According to the nifurtimox production plant project report, the major raw materials for nifurtimox production include 2 mercaptoethanol, propylene oxide, hydrazine, and 5 nitrofurfural.

Production Process of Nifurtimox

The extensive nifurtimox production cost report consists of the following industrial production process:

1. Production from 2 mercaptoethanol: The production process of nifurtimox begins with the reaction of 2 mercaptoethanol and propylene oxide under alkaline conditions to form a hydroxyalkyl sulfide intermediate. Then, this intermediate is cyclised through intramolecular dehydration to produce a sulfur containing ring compound, which is subsequently oxidised to introduce the dioxide functional group. The oxidised compound is reacted with hydrazine to convert it into an amino substituted thiomorpholine derivative. In the final step, this amine reacts with 5 nitrofurfural to form the corresponding hydrazone, which forms nifurtimox as the final product.

Nifurtimox is a nitrofuran derivative that appears as a yellow to orange powder that is soluble in dimethyl sulfoxide (DMSO). The molecular formula of the compound is C10H13N3O5S, and its molar mass is 287.29 g/mol. Its density is approximately 1.47 g/cm³, and it has a water solubility of about 33 g/L. The compound has a melting point of 177–183 degrees Celsius and a boiling point of approximately 550 degrees Celsius. It is marketed under the trade name Lampit. The compound is classified as a combustible solid and is considered moderately toxic. Long-term use may cause adverse effects, including gastrointestinal disturbances such as nausea and vomiting, as well as neurological side effects like insomnia, vertigo, and nervous excitation. It is contraindicated in individuals with severe liver or kidney disease and those with a history of neurological or psychiatric disorders.